Physicians' Academy for Cardiovascular Education

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

This lecture was part of a CME accredited symposium: PCSK9 inhibition in clinical lipid management: A critical review of evidence and opportunities held at ESC 2016 in Rome

Educational information

Educational objectives of this symposium were to:

-Understand the implications of new ESC guidelines for lipid management

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Faculty & Disclosures

Prof. John J.P. Kastelein is Professor of Medicine and chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease

Funding

Supported by unrestricted educational grants from Amgen, Pfizer, and Sanofi-Regeneron.

Also watch lecture: PCSK9, the short track road from discovery as drug target towards the clinic, by Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France Also watch lecture: A clinical perspective on PCSK9 inhibition: What do we know an what can we expect? by Paul M Ridker, MD – BWH, Harvard Medical School, Boston, MA, USA